Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yi Huang
Observed name:
Huang, Yi
Institution:
Hubei Cancer Hospital
Observed institution:
Hubei Cancer Hospital
ORCID:
0000-0003-4707-5213
Observed ORCID:
0000-0003-4707-5213
OpenAlex ID:
A5101776131
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
2025
·
Lingying Wu
, Jing Wang
, et al.
·
CA A Cancer Journal for Clinicians
·
15
PDF
Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018.
2024
·
Guangwen Yuan
, Guiling Li
, et al.
·
Journal of Clinical Oncology
·
15
PDF
IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: Updated results from a phase I trial.
2025
·
Jin Shu
, Tao Zhu
, et al.
·
Journal of Clinical Oncology
·
5
PDF
Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors.
2025
·
Zhiye Zhang
, Xinjun Liang
, et al.
·
Journal of Clinical Oncology
·
3
Abstract 5180: A randomized, double-blind, placebo-controlled phase III study to evaluate AK104 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer
2022
·
Xiaohua Wu
, Jing Wang
, et al.
·
Cancer Research
·
3
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
2022
·
Jian Li
, Ye Xu
, et al.
·
Journal of Clinical Oncology
·
2
T-Bren (BL-M07D1) in patients with recurrent or metastatic (R/M) ovarian cancer: Results from two phase II studies.
2026
·
Gong-Yi Zhang
, Danbo Wang
, et al.
·
Journal of Clinical Oncology
·
1
First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.
2024
·
Ning Li
, Jifang Gong
, et al.
·
Journal of Clinical Oncology
·
1
Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroup (127)
2022
·
Dong Wang
, Naiyi Zhang
, et al.
·
Gynecologic Oncology
·
1
Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial
2026
·
Guangyi Jiang
, Danqing Wang
, et al.
·
Journal of Ovarian Research
Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial
2026
·
Xingzhe Liu
, Dan Liu
, et al.
·
Journal of Ovarian Research
Show more works
View as search
Works count:
15
Citation count:
46
H-index:
3
I10-index:
2
Year
Topic
Type